Blog

Evidence-Based IBS-C Management: Natural Products and Meal Timing Irritable bowel syndrome with constipation is a complex disorder driven by gut-brain a…

Rifaximin Leads in IBS-D and SIBO Treatment with 16.7% Adverse Events A 2026 systematic review of 55 clinical studies confirms rifaximin as the most eff…

Breaking the Relapse Cycle: Prokinetics for SIBO Prevention Small Intestinal Bacterial Overgrowth is frustratingly recurrent

New IBS-C Treatment Management Focuses on Gut-Brain Axis Dysfunction Irritable bowel syndrome with constipation affects millions, marked by abdominal pa…

Rifaximin Shows 16.7% Adverse Event Rate in Largest SIBO-IBS Antibiotic Review A 2026 systematic review analyzed 55 studies to compare three common anti…

Irritable bowel syndrome with constipation presents a complex clinical challenge

Rifaximin Achieves Highest Efficacy for IBS-D and SIBO, According to 2026 Review Rifaximin demonstrated the most consistent efficacy against SIBO and IB…

Irritable bowel syndrome with constipation (IBS-C) is a complex condition involving multiple body systems

Rifaximin Leads in IBS-D and SIBO Treatment, Per 55-Study Systematic Review A 2026 systematic review led by gastroenterologist Qamer Shah and medical tu…

IBS-C Treatment Advances: Natural Products and Meal Timing in Focus Irritable bowel syndrome with constipation (IBS-C) is a complex disorder where chron…

SIBO and IBS Overlap: Rifaximin Leads in Efficacy with a 16.7% Adverse Event Rate A 2026 systematic review analyzed 55 studies to compare three antibiot…

A 2026 review from researchers at Heliopolis University and Cairo University provides a detailed map of the complex pathophysiology driving irritable bo…